Pharma / Biotech

Xpovio Approved to Treat Relapsed or Refractory DLBCL

The FDA granted accelerated approval to selinexor (Xpovio, Karyopharm) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. 

Source link

Related posts

Effect of Smoking Cessation on the Pharmacokinetics and Pharmacodynamics of Clopidogrel after PCI: The Smoking Cessation Paradox Study.


PAROXETINE (Paroxetine Hydrochloride Hemihydrate) Tablet, Film Coated [REMEDYREPACK INC.]


NIFEDIPINE Tablet, Film Coated, Extended Release [Mylan Pharmaceuticals Inc.]


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World